Calliditas Therapeutics AB announced interim data from the proof-of-concept Phase 2 trial in patients with squamous cell carcinoma of the head and neck with its lead NOX 1 and 4 inhibitor product candidate, setanaxib.
Calliditas Therapeutics AB announced interim data from the proof-of-concept Phase 2 trial in patients with squamous cell carcinoma of the head and neck with its lead NOX 1 and 4 inhibitor product candidate, setanaxib.